A Budget Impact Analysis of An Increased Uptake of Alemtuzumab From The UK NHS Perspective

OBJECTIVES: To estimate the impact of increased use of alemtuzumab 12 mg/day in the treatment of adult RRMS patients (per its marketing authorization) on the UK National Health Service (NHS) budget. METHODS: A budget impact analysis was conducted for an average of 121,200 RRMS patients in the UK over a 5-year time horizon (start year: 2017) from the NHS payer perspective. The number of RRMS patients was derived from UK Office of National Statistics (201S) by considering prevalence and incidence of RRMS in the UK. Five direct costs considered were treatment/administration, resource use/monitoring, adverse events, disability progression (assessed by Expanded Disability Status Scale scores), and relapse. The model compared the cost difference in each year under two different market scenarios: current market mix, in which the market share of alemtuzumab 12 mg/day was projected to remain consistent with current shares (2017: 1.6%; 2018: 1.8%; 2019-2021:1.5%), and an alternative market mix, in which market share of alemtuzumab 12 mg/day was forecasted to increase 0% to 1% per year (2017:2.6%; 2018:2.2%; 2C19: 2.1%; 2020-2021:1.5%). RESULTS: Using the alternative market mix in the UK NHS payer perspective, alemtuzumab starts saving in Year 3 (2019) compared with :he current market mix, with an average annual total cost saving of £10,976,253 over 5 years for all RRMS population. The annual total costs for the first 2 years increased with the alternative mix, which can be explained by initial high upfront costs of alemtuzumab. However, these increases are offset by the reduction in drug usage in subsequent years, leading to an overall cost saving. CONCLUSIONS: From the UK NHS perspective, compared to the current market mix, the alternative market mix with increased uptake of alemtuzumab leads to an average annual saving of £10 million over 5 years, starting from Year 3 (2019). STUDY SUPPORT: Sanofi